US 12,194,087 B2 · Method of inhibiting enveloped virus binding to target cells by incorporating P-selectin glycoprotein ligand-1 (PSGL-1) into virions

Abstract

Embodiments relate to a method comprising (a) expressing a vector comprising a PSGL-1 (P-selectin glycoprotein ligand-1) or a mutant thereof in a VPC (virus producing cell); and blocking a virus infection by inactivating an infectivity of a released virions from the VPC; or (b) expressing a glycoprotein or a mutant thereof in the VPC; blocking the virus infection by preventing binding of the released virions to a target cell; inactivating infectivity of the released virions; and targeting a viral infection. Other embodiments relate to (1) a broad-spectrum anti-viral product comprising: a vector expressing a glycoprotein or a mutant thereof in a VPC; and blocking a virus infection by inactivating infectivity of a released virion from the VPC; and (2) a vaccine comprising a viral particle is configured to a live attenuated or an inactivated or a non-infectious, wherein the viral particle are produced in a VPC.

Claims20

Dependent claims

A method comprising:

taking P-selectin glycoprotein ligand-1 (PSGL-1) or a mutant thereof comprising an extracellular N-terminal domain (NT) comprising at least one decameric repeat (DR) region, and a transmembrane (TM) region, wherein the DR region comprises at least one proline and more than one O-glycosylated threonine, wherein the mutant exhibits an antiviral activity;
co-expressing a retroviral vector of a retrovirus and an expression vector comprising the PSGL-1 or the mutant thereof in a virus-producing cell (VPC) such that the PSGL-1 or the mutant thereof is incorporated into a viral particle during a virion assembly and expressed on a surface of virions produced due to introduction of the retroviral vector in the VPC;
wherein presence of the PSGL-1 or the mutant thereof on the surface of the virions blocks binding of the virions to its cognate receptor to inactivate a viral infection of the retrovirus;
and
wherein the VPC comprises a cell line of a human.

2 more elements

Dependencies are inferred from the claim text.

Method of inhibiting enveloped virus binding to target cells by incorporating P-selectin glycoprotein ligand-1 (PSGL-1) into virions

Life of this patent

Method of inhibiting enveloped virus binding to target cells by incorporating P-selectin glycoprotein ligand-1 (PSGL-1) into virions

Life of this patent

Abstract

Claims20